Evaluation of Dosing Interval of Higher Doses of Ranibizumab

Completed · Phase 4

Conditions studied: Macular Degeneration, Choroidal Neovascularization

In brief

Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).

Key facts

Study ID

NCT00533520

Run by

Brandon G. Busbee, MD

People needed

37

Starts

2007-09-01

Expected to finish

2013-11-01

Last updated by the study team

2013-11-25

Who can join

Age: 50 and older, up to 95. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Treatment naive macular degeneration patients with choroidal neovascularization
• >50 years old
• Visual acuity 20/40 to 20/320

You may not qualify if…

• Pregnancy
• Previous history of thromboembolic event including myocardial infarction or stroke

Where it is running

• Tennessee Retina, P.C. — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.